United Therapeutics Stock Fair Value Calculation – UNITED THERAPEUTICS Reports 27.8% Increase in Q2 2023 Revenue of USD 596.5 Million

August 15, 2023

☀️Earnings Overview

On August 2 2023, UNITED THERAPEUTICS ($NASDAQ:UTHR) reported total revenue of USD 596.5 million for the second quarter of its fiscal year 2023, an increase of 27.8% compared to the same period from the previous year. Net income also saw considerable growth, amounting to USD 259.2 million, a rise of 123.4% from the prior year.

Analysis – United Therapeutics Stock Fair Value Calculation

GoodWhale is proud to provide an analysis of UNITED THERAPEUTICS‘s financials. Our proprietary Valuation Line suggests that the intrinsic value of UNITED THERAPEUTICS shares is around $230.0. We recommend investors to consider this data before making any decisions about UNITED THERAPEUTICS stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for United Therapeutics. More…

    Total Revenues Net Income Net Margin
    2.11k 871.5 41.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for United Therapeutics. More…

    Operations Investing Financing
    867.9 -731.6 135.8
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for United Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    6.68k 1.27k 115.34
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for United Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    13.8% 25.2% 55.4%
    FCF Margin ROE ROA
    31.9% 13.9% 10.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s main competitors are MannKind Corp, Sanofi SA, Eli Lilly and Co.

    – MannKind Corp ($NASDAQ:MNKD)

    MannKind Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics for diabetes and cancer. Its product pipeline includes Afrezza, MK-1293, and MK-3655. The company was founded by Alfred E. Mann on February 3, 1991 and is headquartered in Valencia, CA.

    – Sanofi SA ($OTCPK:SNYNF)

    Sanofi has a market cap of 98.97B as of 2022 and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and was founded in 1904. Sanofi is engaged in the research, development, manufacturing, and marketing of pharmaceutical products for the treatment of patients in the areas of cardiovascular, central nervous system, diabetes, internal medicine, oncology, and thrombosis.

    – Eli Lilly and Co ($NYSE:LLY)

    Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

    The company’s market cap is $312.67 billion as of 2022 and its return on equity is 45.88%.


    United Therapeutics has had a successful second quarter of fiscal year 2023, with total revenue reaching USD 596.5 million, a 27.8% increase from the same period in the prior year. Net income also increased significantly, up 123.4% year-over-year to USD 259.2 million. Investors may be encouraged by United Therapeutics’ second quarter results and the company’s growth potential in the coming quarters. The company’s strong financial performance indicates that United Therapeutics is well-positioned to meet its strategic objectives and continue delivering shareholder value.

    Recent Posts

    Leave a Comment